Key Insights

Highlights

Treatment Research

3 treatments under study, led by Loncastuximab Tesirine

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT07197307Phase 2RecruitingPrimary

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Showing all 1 trials

Research Network

Common Treatments

  • Loncastuximab Tesirine1
  • Loncastuximab Tesirine And Epcoritamab1
  • Epcoritamab1

Active Sponsors

  • Universität Münster1
  • AbbVie1
  • Sobi, Inc.1

Related Conditions

  • Follicular Lymphoma Fl Grade 3b1
  • Highgrade Bcell Lymphoma Hgbl1

Activity Timeline